menu
    • menu
    [{"orgOrder":0,"company":"PharmaLogic","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Agreement","leadProduct":"212-Pb NG001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"PharmaLogic \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"PharmaLogic \/ ARTBIO"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"UPMC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PharmaLogic \/ UPMC","highestDevelopmentStatusID":"2","companyTruncated":"PharmaLogic \/ UPMC"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"Viewpoint Molecular Targeting","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Agreement","leadProduct":"VMT01","moa":"MC1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaLogic \/ Viewpoint Molecular Targeting","highestDevelopmentStatusID":"4","companyTruncated":"PharmaLogic \/ Viewpoint Molecular Targeting"}]

    Find Clinical Drug Pipeline Developments & Deals by PharmaLogic

    Menu

    PharmaLogic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PharmaLogic

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            PharmaLogic

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb NG001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : ARTBIO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ARTBIO and PharmaLogic Announce Supply Agreement for AB001

                            Details : PharmaLogic will assist ARTBIO with radiochemistry and supply finished radiopharmaceutical products for future Phase I and II clinical trials of AB001 (212Pb-NG001).

                            Product Name : AB001

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            December 01, 2024

                            Lead Product(s) : 212-Pb NG001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : ARTBIO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PharmaLogic

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            PharmaLogic

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : UPMC

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            UPMC and PharmaLogic Partner to Develop Novel Radiopharmaceuticals at New Facility in Pittsburgh

                            Details : The collaboration aims to facilitate the development of novel radiopharmaceuticals for the diagnosis and treatment of cancer, cardiovascular and other diseases.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 21, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : UPMC

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PharmaLogic

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            PharmaLogic

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VMT01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Viewpoint Molecular Targeting

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Perspective Therapeutics And Pharmalogic Announce Collaboration For The Development And Production Of Theranos...

                            Details : Under the terms of the agreement, PharmaLogic will produce and supply doses of theranostic candidates, VMT-01 and VMT-α-NET for use in Perspective’s early-stage clinical trials, for the diagnosis and treatment of metastatic melanoma and neuroendocrine...

                            Product Name : VMT01

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            March 14, 2023

                            Lead Product(s) : VMT01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Viewpoint Molecular Targeting

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth